Trial Profile

Surufatinib and Sintilimab in Combination With Capecitabine in Patients With Previously Treated Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma : a Single-arm, a Single-center , Phase 2 Trial

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 06 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Capecitabine (Primary) ; Regorafenib (Primary) ; Sintilimab (Primary) ; Surufatinib (Primary)
Indications Adenocarcinoma; Appendiceal cancer; Carcinoma; Intestinal cancer
Focus Therapeutic Use

30 Apr 2025 Results (data cut off December 31, 2024, n=9) assessing efficacy and safety of surufatinib, a multi-target tyrosine kinase inhibitor targeting VEGFR1-3, FGFR1, and CSF-1R, in combination with sintilimab and capecitabine for advanced SBA and appendiceal carcinoma, presented at the 116th Annual Meeting of the American Association for Cancer Research.
28 Jul 2022 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com